Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.46 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.46 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BHMT | Q93088 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21447999 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL874270 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL18954338 | 0.98 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL6447117 | 0.84 | SLC7A5 (0.60) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL6028073 | 0.84 | — | — | |
| SCHEMBL6027700 | 0.84 | — | — | |
| SCHEMBL8244 | 0.84 | — | — | |
| SCHEMBL5322808 | 0.83 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL6663362 | 0.83 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL30391170 | 0.81 | GRIK1 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220142959-A1 | LEUCINE, ACETYL LEUCINE, AND RELATED ANALOGS FOR TREATING DISEASE | Intrabio Ltd. (GB) | 2022-05-12 | — | — | US | claimed |
| CN-114040757-A | Leucine, acetylleucine and related analogs for the treatment of disease | 内在生物技术有限公司 | 2022-02-11 | — | — | CN | claimed |
| EP-3934637-A1 | LEUCINE, ACETYL LEUCINE, AND RELATED ANALOGS FOR TREATING DISEASE | IntraBio Ltd (GB) | 2022-01-12 | — | — | EP | claimed |
| EP-3752496-A1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES, INC. (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161280-A1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES, INC. (US) | 2019-08-22 | — | — | WO | claimed |
| WO-2010128518-A2 | NOVEL PROCESS FOR THE PREPARATION OF CISATRACURIUM BESYLATE | GLAND PHARMA LIMITED (IN) | 2010-11-11 | — | — | WO | claimed |
| WO-2003080048-A1 | (-)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
| US-20260069562-A1 | THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR TREATING NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS | INTRABIO LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260027077-A1 | PHARMACEUTICAL COMPOSITIONS AND USES DIRECTED TO LYSOSOMAL STORAGE DISORDERS | INTRABIO LTD (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4650003-A2 | COMBINATION THERAPY WITH ACETYL-LEUCINE AND MIGLUSTAT FOR TREATING A LYSOSOMAL STORAGE DISEASE | IntraBio Ltd (GB) | 2025-11-19 | — | — | EP | disclosed |
| US-12458614-B2 | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders | INTRABIO LTD (GB) | 2025-11-04 | — | — | US | disclosed |
| US-12433862-B2 | Pharmaceutical compositions and uses directed to lysosomal storage disorders | INTRABIO LIMITED (GB) | 2025-10-07 | — | — | US | disclosed |
| WO-2007029107-A1 | ISOQUINOLINES DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2007-03-15 | — | — | WO | disclosed |
| EP-1732898-A1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | Analytecon S.A. (CH) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006093719-A1 | AN EFFICIENT AND STEREOSELECTIVE PROCESS FOR LARGE SCALE SYNTHESIS OF 3-(R)-3- (2,3-DIHYDROBENZOFURAN-5-YL)-1,2,3,4- TETRAHYDROPYRROLO{3,4-B}QUINOLIN-9-ONE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-08 | — | — | WO | disclosed |
| WO-2005087743-A1 | TETRAHYDROISOQUINOLINE-AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON S.A. (CH) | 2005-09-22 | — | — | WO | disclosed |
| EP-1318994-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | Schering Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024659-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTGONISTS | SCHERING CORPORATION (US) | 2002-03-28 | — | — | WO | disclosed |
| US-4259441-A | Process for resolving D, L-leucine | ETHYL CORPORATION (US) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069562-A1 | THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR TREATING NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS | CLN6, LIMS1, CTSA | SLC7A5 25/4885SLC1A3 86/4885SLC1A2 104/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | SLC7A5 1709/4885SLC1A3 2941/4885SLC1A2 2762/4885 |
| US-20260027077-A1 | PHARMACEUTICAL COMPOSITIONS AND USES DIRECTED TO LYSOSOMAL STORAGE DISORDERS | MAN2B1, GBA2, CLN6 | SLC7A5 89/4885SLC1A3 150/4885SLC1A2 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.